Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery
Purpose To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery. Methods This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery...
Gespeichert in:
Veröffentlicht in: | Eye 2000-10, Vol.14 (5), p.757-760 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 760 |
---|---|
container_issue | 5 |
container_start_page | 757 |
container_title | Eye |
container_volume | 14 |
creator | Rainer, Georg Menapace, Rupert Findl, Oliver Georgopoulos, Michael Kiss, Barbara Heinze, Georg |
description | Purpose
To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery.
Methods
This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively.
Results
The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg;
p
= 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p < 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group (
p
= 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups.
Conclusions
2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery. |
doi_str_mv | 10.1038/eye.2000.198 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72491160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72491160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</originalsourceid><addsrcrecordid>eNp1kU9rFjEQh4Mo9m315lkCQk9unWT_5ijFWqFQEAVvSzaZtCm7yZrsKm-_i9_VWd6XejKXIckzv4FnGHsj4EJA2X3APV5IALqp7hnbibpWRQuiec52oGoopJQ_Tthpzg8AompbeMlOBJ2mUWrH_nzVwcbJZ7Tc4TjG35wCuYnTrJPPMfDo-HKPHJ1Ds_hfGDDn7dHG9BhHPXmLnDK4npM2Ywze-oCcGn1Yko5mHXXic6KuNSF3cZvhwx2f77WJOK1j9s4bvXhqoaIpZeHE3mHav2IvnB4zvj7WM_b96tO3y-vi5vbzl8uPN4WpRLMUaKHpBihrZwfZQCntYCtZCjXUdFXQViV0yolOtk7XdVk3IAQIBAmtagdbnrHzQ-6c4s8V89KTEUM6dMC45r6VlSJjQOD7A2hSzDmh6-fkJ532vYB-W0dP9vptHT2tg_C3x9x1mND-g4_-CXh3BHQ2enRJB-PzE9dRopJEFQcq00cgMf1DXFMgI_8byw980AtJf4ojaGM25C9I6rAV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72491160</pqid></control><display><type>article</type><title>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SAGE Complete A-Z List</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rainer, Georg ; Menapace, Rupert ; Findl, Oliver ; Georgopoulos, Michael ; Kiss, Barbara ; Heinze, Georg</creator><creatorcontrib>Rainer, Georg ; Menapace, Rupert ; Findl, Oliver ; Georgopoulos, Michael ; Kiss, Barbara ; Heinze, Georg</creatorcontrib><description>Purpose
To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery.
Methods
This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively.
Results
The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg;
p
= 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p < 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group (
p
= 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups.
Conclusions
2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1559-7016</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2000.198</identifier><identifier>PMID: 11116699</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adrenergic alpha-Agonists - therapeutic use ; Aged ; Aged, 80 and over ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Carbonic Anhydrase Inhibitors - therapeutic use ; clinical-study ; Clonidine - analogs & derivatives ; Clonidine - therapeutic use ; Eye ; Female ; Humans ; Laboratory Medicine ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Ocular Hypertension - etiology ; Ocular Hypertension - prevention & control ; Ophthalmology ; Phacoemulsification - adverse effects ; Pharmaceutical Sciences/Technology ; Pharmacology. Drug treatments ; Prospective Studies ; Sulfonamides - therapeutic use ; Surgery ; Surgical Oncology ; Thiophenes - therapeutic use</subject><ispartof>Eye, 2000-10, Vol.14 (5), p.757-760</ispartof><rights>College of Ophthalmologists 2000</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</citedby><cites>FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/eye.2000.198$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/eye.2000.198$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=803892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11116699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rainer, Georg</creatorcontrib><creatorcontrib>Menapace, Rupert</creatorcontrib><creatorcontrib>Findl, Oliver</creatorcontrib><creatorcontrib>Georgopoulos, Michael</creatorcontrib><creatorcontrib>Kiss, Barbara</creatorcontrib><creatorcontrib>Heinze, Georg</creatorcontrib><title>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</title><title>Eye</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Purpose
To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery.
Methods
This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively.
Results
The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg;
p
= 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p < 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group (
p
= 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups.
Conclusions
2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.</description><subject>Adrenergic alpha-Agonists - therapeutic use</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carbonic Anhydrase Inhibitors - therapeutic use</subject><subject>clinical-study</subject><subject>Clonidine - analogs & derivatives</subject><subject>Clonidine - therapeutic use</subject><subject>Eye</subject><subject>Female</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - etiology</subject><subject>Ocular Hypertension - prevention & control</subject><subject>Ophthalmology</subject><subject>Phacoemulsification - adverse effects</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Sulfonamides - therapeutic use</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Thiophenes - therapeutic use</subject><issn>0950-222X</issn><issn>1559-7016</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9rFjEQh4Mo9m315lkCQk9unWT_5ijFWqFQEAVvSzaZtCm7yZrsKm-_i9_VWd6XejKXIckzv4FnGHsj4EJA2X3APV5IALqp7hnbibpWRQuiec52oGoopJQ_Tthpzg8AompbeMlOBJ2mUWrH_nzVwcbJZ7Tc4TjG35wCuYnTrJPPMfDo-HKPHJ1Ds_hfGDDn7dHG9BhHPXmLnDK4npM2Ywze-oCcGn1Yko5mHXXic6KuNSF3cZvhwx2f77WJOK1j9s4bvXhqoaIpZeHE3mHav2IvnB4zvj7WM_b96tO3y-vi5vbzl8uPN4WpRLMUaKHpBihrZwfZQCntYCtZCjXUdFXQViV0yolOtk7XdVk3IAQIBAmtagdbnrHzQ-6c4s8V89KTEUM6dMC45r6VlSJjQOD7A2hSzDmh6-fkJ532vYB-W0dP9vptHT2tg_C3x9x1mND-g4_-CXh3BHQ2enRJB-PzE9dRopJEFQcq00cgMf1DXFMgI_8byw980AtJf4ojaGM25C9I6rAV</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>Rainer, Georg</creator><creator>Menapace, Rupert</creator><creator>Findl, Oliver</creator><creator>Georgopoulos, Michael</creator><creator>Kiss, Barbara</creator><creator>Heinze, Georg</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</title><author>Rainer, Georg ; Menapace, Rupert ; Findl, Oliver ; Georgopoulos, Michael ; Kiss, Barbara ; Heinze, Georg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adrenergic alpha-Agonists - therapeutic use</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carbonic Anhydrase Inhibitors - therapeutic use</topic><topic>clinical-study</topic><topic>Clonidine - analogs & derivatives</topic><topic>Clonidine - therapeutic use</topic><topic>Eye</topic><topic>Female</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - etiology</topic><topic>Ocular Hypertension - prevention & control</topic><topic>Ophthalmology</topic><topic>Phacoemulsification - adverse effects</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Sulfonamides - therapeutic use</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Thiophenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rainer, Georg</creatorcontrib><creatorcontrib>Menapace, Rupert</creatorcontrib><creatorcontrib>Findl, Oliver</creatorcontrib><creatorcontrib>Georgopoulos, Michael</creatorcontrib><creatorcontrib>Kiss, Barbara</creatorcontrib><creatorcontrib>Heinze, Georg</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Eye</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rainer, Georg</au><au>Menapace, Rupert</au><au>Findl, Oliver</au><au>Georgopoulos, Michael</au><au>Kiss, Barbara</au><au>Heinze, Georg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</atitle><jtitle>Eye</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>14</volume><issue>5</issue><spage>757</spage><epage>760</epage><pages>757-760</pages><issn>0950-222X</issn><eissn>1559-7016</eissn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Purpose
To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery.
Methods
This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively.
Results
The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg;
p
= 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p < 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group (
p
= 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups.
Conclusions
2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11116699</pmid><doi>10.1038/eye.2000.198</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0950-222X |
ispartof | Eye, 2000-10, Vol.14 (5), p.757-760 |
issn | 0950-222X 1559-7016 1476-5454 |
language | eng |
recordid | cdi_proquest_miscellaneous_72491160 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SAGE Complete A-Z List; SpringerLink Journals - AutoHoldings |
subjects | Adrenergic alpha-Agonists - therapeutic use Aged Aged, 80 and over Antihypertensive Agents - therapeutic use Biological and medical sciences Carbonic Anhydrase Inhibitors - therapeutic use clinical-study Clonidine - analogs & derivatives Clonidine - therapeutic use Eye Female Humans Laboratory Medicine Male Medical sciences Medicine Medicine & Public Health Middle Aged Ocular Hypertension - etiology Ocular Hypertension - prevention & control Ophthalmology Phacoemulsification - adverse effects Pharmaceutical Sciences/Technology Pharmacology. Drug treatments Prospective Studies Sulfonamides - therapeutic use Surgery Surgical Oncology Thiophenes - therapeutic use |
title | Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A26%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomised%20fellow%20eye%20comparison%20of%20the%20effectiveness%20of%20dorzolamide%20and%20apraclonidine%20on%20intraocular%20pressure%20following%20phacoemulsification%20cataract%20surgery&rft.jtitle=Eye&rft.au=Rainer,%20Georg&rft.date=2000-10-01&rft.volume=14&rft.issue=5&rft.spage=757&rft.epage=760&rft.pages=757-760&rft.issn=0950-222X&rft.eissn=1559-7016&rft.coden=EYEEEC&rft_id=info:doi/10.1038/eye.2000.198&rft_dat=%3Cproquest_cross%3E72491160%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72491160&rft_id=info:pmid/11116699&rfr_iscdi=true |